Glucose Intolerance
Conditions
Brief summary
This study was a double-blind, randomized, placebo-controlled, clinical trial with two parallel groups. Participants reported to a single investigational center in Ohio (i.e., The Center for Applied Health Sciences) during the 12 week trial.
Detailed description
This study was a double-blind, randomized, two-arm, placebo-controlled trial of apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences). Subjects will attend four study visits. During Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work \[also HgA1c, insulin\], background baseline diet). Over the next 12 weeks, subjects will attend Visits 2-4, wherein assessments of serum glucose, insulin, HOMA-IR, 2-hour glucose tolerance test (GTT), NMR profile, HgA1c, C-reactive protein, adiponectin, ferritin, waist circumference, quality of life questionnaire, and various visual analog scales for appetite, satiety, and cravings will be made (see Study Schematic for details). Comprehensive side effect profile/ adverse event monitoring will take place throughout the study duration. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.
Interventions
DIETARY_SUPPLEMENTActive
Blend of chromium, amla fruit extract, and citrus bioflavonoids
DIETARY_SUPPLEMENTPlacebo
Maltodextrin tablet
Sponsors
The Center for Applied Health Sciences, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)
Masking description
Supplements were blinded by the sponsor prior to initiation of any research activities. All research activities, including statistical analysis, were completed by the research team while blinded.
Intervention model description
All participants were randomly assigned to receive either the active product or a placebo. Subjects were instructed to consume their respective supplement daily for 12 weeks, approximately 15-30 minutes prior to their evening meal.
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Provide voluntary signed and dated informed consent. * Be in good health as determined by medical history and routine blood chemistries. * Age between the ages of 21 and 65 (inclusive). * Body Mass Index of 18.5-34.99 (inclusive). * Body weight of at least 120 pounds. * Fasting blood sugar of 100-125 (inclusive) OR HgA1c of 5.7-6.4% (inclusive). * Normotensive (seated, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility. * Normal seated, resting heart rate (\<90 per minute). * Willing to duplicate their previous 24-hour diet, refrain from caffeine for 12 hrs and exercise
Exclusion criteria
* History of unstable or new-onset cardiovascular or cardiorespiratory disease. * History of diabetes, or other endocrine disorder. * Fasting blood sugar of \> 125 mg/dL or HgA1c of \> 6.4%. * History of use of medications or dietary supplements known to affect glycemia or insulinemia. * History of hyperparathyroidism or an untreated thyroid disease. * History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin). * Prior gastrointestinal bypass surgery (Lapband), etc. * Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU). * Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). * Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of-Analysis. * Currently participating in another research study with an investigational product or have been in another research study in the past 30 days. * Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose kinetics | Change from baseline to 12 weeks. | Serum glucose response during a two hour oral sucrose tolerance test. |
| Insulin kinetics | Change from baseline to 12 weeks. | Serum insulin response during a two hour oral sucrose tolerance test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adiponectin | Change from baseline to 12 weeks. | Serum adiponectin |
| Ferritin | Change from baseline to 12 weeks. | Serum ferritin |
| Appetite | Change from baseline to 12 weeks. | Appetite as measured by a 10 cm visual analogue scale, where higher values represent greater appetite. Values range from 1-10, and a greater appetite score would be a worse outcome in these participants. |
| Hemoglobin A1c (HgA1c) | Change from baseline to 12 weeks. | Serum HgA1c |
| Food cravings | Change from baseline to 12 weeks. | Food cravings as measured by a 10 cm visual analogue scale, where higher values represent greater food cravings. Values range from 1-10, and a greater food cravings score would be a worse outcome in these participants. |
| Sweet food cravings | Change from baseline to 12 weeks. | Sweet food cravings as measured by a 10 cm visual analogue scale, where higher values represent greater sweet food cravings. Values range from 1-10, and a greater sweet food cravings score would be a worse outcome in these participants. |
| Blood urea nitrogen to creatinine ratio | Change from baseline to 12 weeks. | The ratio of blood urea nitrogen to creatinine in serum. |
| Satiety | Change from baseline to 12 weeks. | Satiety as measured by a 10 cm visual analogue scale, where higher values represent greater satiety. Values range from 1-10, and a greater satiety score would be a better outcome in these participants. |
| C-reactive protein | Change from baseline to 12 weeks. | Serum C-reactive protein |
Countries
United States
Outcome results
None listed